USSTOCK.TODAY
Pre-Market
Log in Sign up

Revolution Medicines Obtains US Approval for Pancreatic Cancer Treatment Razonc

The Motley Fool +2 · ·by G4L

RVMD Revolution Medicines Inc
$193.06 -3.54%
View chart & analysis →
  1. 1Revolution Medicines obtained US approval for Razonc for specific pancreatic cancer patients in August.
  2. 2In Phase 3 clinical trials, Razonc recorded a median overall survival of 13.2 months, outperforming 6.7 months for cytotoxic chemotherapy.
  3. 3The Duquesne Family Office recorded a 26.5% increase in its stake during the second quarter.

So what's the key point?

Revolution Medicines received US approval for its pancreatic cancer treatment, Razonc. This drug has drawn investor interest by extending survival by 6.7 months compared to existing treatments.

Source The Motley Fool +2 · View original ↗

Related 3-line summaries

Revolution Medicines Receives FDA Approval for Pancreatic Cancer Treatment, Raising Royalty Pharma Revenue Expectations The Motley Fool +1 · 2d agoRevolution Medicines beats revenue estimates with RASONQUE launch Earnings Whispers +3 · 6d agoRevolution Medicines Receives Pancreatic Cancer Treatment Approval and Increases Stake The Motley Fool +1 · Oct 29
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news